EUVIMEDEUVIMED entdecken
Crossref

Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024

Megan G Hofmeister iD, Hasan Symum, Brooke E Swanson iD, Laurie K Barker iD, Yuna Zhong, Harvey W Kaufman iD, William W Thompson iD, William A Meyer iD, Neil Gupta

Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e960-e966

DOI: 10.1093/cid/ciag007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 08.01.2026. Verfasst von Megan G Hofmeister und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis C Antibodies, Hepacivirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory.

Methods

We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18–≤75 years. We randomly sampled within 2 age groups (18–≤49 years and 50–≤75 years) during November 2023–September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age–sex distribution of the United States.

Results

Among adults aged 18–≤75 years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%–3.0%), corresponding to 6 887 000 (95% CI, 6 622 000–7 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%–.8%), corresponding to 1 698 000 (95% CI, 1 554 000–1 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%–66.9%]) than older adults (81.1% [95% CI, 78.9%–83.3%]).

Conclusions

In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023–September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CHepatitis C AntibodiesHepacivirusHumansMiddle AgedFemaleAdultMalePrevalenceCross-Sectional StudiesAdolescentUnited StatesYoung AdultAgedRNA, ViralLaboratories

Stichwörter der Autor:innen

HCV infectionhepatitis Cprevalenceremnant sera

Substanzen

Hepatitis C AntibodiesRNA, Viral

Autor:innen und Institutionen

  • Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Medical Affairs, Quest Diagnostics, Secaucus, New Jersey, USA.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Megan G Hofmeister, Brooke E Swanson, Laurie K Barker, Harvey W Kaufman, William W Thompson, William A Meyer

Förderung

  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Hofmeister, M. G., Symum, H., Swanson, B. E., Barker, L. K., Zhong, Y., Kaufman, H. W., Thompson, W. W., Meyer, W. A., & Gupta, N. (2026). Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024. Clinical Infectious Diseases, 82(5), e960-e966. https://doi.org/10.1093/cid/ciag007

Vancouver

Hofmeister MG, Symum H, Swanson BE, Barker LK, Zhong Y, Kaufman HW, et al. Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024. Clinical Infectious Diseases. 2026;82(5):e960-e966. doi:10.1093/cid/ciag007

BibTeX
@article{Hofmeister2026,
  author = {Hofmeister, Megan G and Symum, Hasan and Swanson, Brooke E and Barker, Laurie K and Zhong, Yuna and Kaufman, Harvey W and Thompson, William W and Meyer, William A and Gupta, Neil},
  title = {Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {5},
  pages = {e960--e966},
  doi = {10.1093/cid/ciag007}
}
Kostenlos starten →